Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an update.
Chimeric Therapeutics Limited has notified the market of the issue of 16,667,000 unquoted options under an employee incentive scheme, with various exercise prices and expiry dates, effective 12 December 2025. The additional unquoted equity securities expand the company’s pool of staff incentives, aligning employee remuneration with shareholder interests and potentially impacting future capital structure depending on option exercise and subsequent share issuance.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is a biotechnology company listed on the ASX that focuses on developing therapeutic products, likely within the biopharmaceutical or cell therapy space, targeting unmet medical needs in healthcare markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$12.75M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.